Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Aftimos

Showing results (21-30 of 82) with videos related to

Pageof 9
Sort By:
Breast (Edinburgh, Scotland)|February 24, 2018
Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancerChristian Maurer, Arlindo R Ferreira, Samuel Martel, et al.
Acta Oncologica (Stockholm, Sweden)|September 24, 2025
Complete remission with olaparib in BRIP1-mutated metastatic high-grade pleomorphic sarcoma: case study and literature review - an example of a genomic profiling-based tumor treatment, in a cancer type with high unmet clinical needAlexander D J Thooft, Sofie Joris, Celine Jacobs, et al.
Le Journal Medical Libanais. the Lebanese Medical Journal|January 21, 2012
[Chemoradiotherapy in early stage Hodgkin's lymphoma]Georges Farha, Elie Nasr, Marwan Ghosn, et al.
Anti-Cancer Drugs|January 23, 2016
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumorsAhmad Awada, Mario Campone, Andrea Varga, et al.
Cancers|November 11, 2022
Post-Neoadjuvant Treatment Strategies for Patients with Early Breast CancerElisa Agostinetto, Flavia Jacobs, Véronique Debien, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2023
Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysisDiogo Martins-Branco, Guilherme Nader-Marta, Chiara Molinelli, et al.
British Journal of Cancer|August 4, 2020
First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumoursJuan Martin-Liberal, Antoine Hollebecque, Philippe Aftimos, et al.
Future Oncology (London, England)|September 22, 2022
Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2Shom Goel, Antoinette R Tan, Hope S Rugo, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 4, 2019
Extended time interval between diagnosis and surgery does not improve the outcome in patients operated for resection or ablation of breast cancer liver metastasesValerio Lucidi, Ali Bohlok, Gabriel Liberale, et al.
Scientific Reports|March 3, 2016
The current use and attitudes towards tumor genome sequencing in breast cancerI Gingras, A Sonnenblick, E de Azambuja, et al.
Pageof 9

Showing results (21-30 of 82) with videos related to

Sort By:
Pageof 9
Breast (Edinburgh, Scotland)|February 24, 2018
Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancerChristian Maurer, Arlindo R Ferreira, Samuel Martel, et al.
Acta Oncologica (Stockholm, Sweden)|September 24, 2025
Complete remission with olaparib in BRIP1-mutated metastatic high-grade pleomorphic sarcoma: case study and literature review - an example of a genomic profiling-based tumor treatment, in a cancer type with high unmet clinical needAlexander D J Thooft, Sofie Joris, Celine Jacobs, et al.
Le Journal Medical Libanais. the Lebanese Medical Journal|January 21, 2012
[Chemoradiotherapy in early stage Hodgkin's lymphoma]Georges Farha, Elie Nasr, Marwan Ghosn, et al.
Anti-Cancer Drugs|January 23, 2016
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumorsAhmad Awada, Mario Campone, Andrea Varga, et al.
Cancers|November 11, 2022
Post-Neoadjuvant Treatment Strategies for Patients with Early Breast CancerElisa Agostinetto, Flavia Jacobs, Véronique Debien, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2023
Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysisDiogo Martins-Branco, Guilherme Nader-Marta, Chiara Molinelli, et al.
British Journal of Cancer|August 4, 2020
First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumoursJuan Martin-Liberal, Antoine Hollebecque, Philippe Aftimos, et al.
Future Oncology (London, England)|September 22, 2022
Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2Shom Goel, Antoinette R Tan, Hope S Rugo, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 4, 2019
Extended time interval between diagnosis and surgery does not improve the outcome in patients operated for resection or ablation of breast cancer liver metastasesValerio Lucidi, Ali Bohlok, Gabriel Liberale, et al.
Scientific Reports|March 3, 2016
The current use and attitudes towards tumor genome sequencing in breast cancerI Gingras, A Sonnenblick, E de Azambuja, et al.
Pageof 9